OA10777A - Treatment of ovarian estrogen dependent conditions - Google Patents

Treatment of ovarian estrogen dependent conditions Download PDF

Info

Publication number
OA10777A
OA10777A OA60870A OA60870A OA10777A OA 10777 A OA10777 A OA 10777A OA 60870 A OA60870 A OA 60870A OA 60870 A OA60870 A OA 60870A OA 10777 A OA10777 A OA 10777A
Authority
OA
OAPI
Prior art keywords
antiprogestin
analog
administration
treatment
condition
Prior art date
Application number
OA60870A
Other languages
English (en)
Inventor
Gary D Hodgen
Robert F Williams
Daniel Grow
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of OA10777A publication Critical patent/OA10777A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
OA60870A 1994-02-04 1996-07-29 Treatment of ovarian estrogen dependent conditions OA10777A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions

Publications (1)

Publication Number Publication Date
OA10777A true OA10777A (en) 2002-12-23

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60870A OA10777A (en) 1994-02-04 1996-07-29 Treatment of ovarian estrogen dependent conditions

Country Status (29)

Country Link
US (1) US5681817A (de)
EP (1) EP0785792B1 (de)
JP (1) JP3130048B2 (de)
KR (1) KR970700507A (de)
CN (1) CN1144486A (de)
AP (1) AP724A (de)
AT (1) ATE179610T1 (de)
AU (1) AU689229B2 (de)
BG (1) BG62238B1 (de)
BR (1) BR9506606A (de)
CA (1) CA2182183C (de)
CZ (1) CZ291709B6 (de)
DE (1) DE69509544T2 (de)
DK (1) DK0785792T3 (de)
ES (1) ES2132645T3 (de)
FI (1) FI963036A (de)
GR (1) GR3030164T3 (de)
HU (1) HUT74622A (de)
LT (1) LT4182B (de)
LV (1) LV11782B (de)
MD (1) MD1432C2 (de)
NZ (1) NZ281441A (de)
OA (1) OA10777A (de)
PL (1) PL178273B1 (de)
RO (1) RO117420B1 (de)
RU (1) RU2110274C1 (de)
SK (1) SK96296A3 (de)
TJ (1) TJ242B (de)
WO (1) WO1995020972A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114655A (en) * 1994-07-22 2005-08-31 Hampton Roads Medical College USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6274573B1 (en) 1997-10-17 2001-08-14 Mochida Pharmaceutical Co., Ltd. Method of treatment for uterine leiomyoma
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
HUP0202429A3 (en) * 1999-08-31 2004-04-28 Schering Ag Use of mesoprogestins (progesterone receptor modulators) for the preparation of pharmaceutical compositions for the treatment and prevention of benign hormone dependent gynecological disorders
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2002036144A1 (en) * 2000-10-30 2002-05-10 University Of Zurich Gnrh analogues for treatment of urinary incontinence
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
ES2366654T3 (es) * 2005-02-17 2011-10-24 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. Biofosfonatos para tratar la endometriosis.
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
EP3693376A1 (de) * 2006-10-24 2020-08-12 Allergan Pharmaceuticals International Limited Zusammensetzungen zur unterdrückung der endometriumproliferation
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
AU2008300199B2 (en) * 2007-09-20 2013-09-12 Lapidot Medical Import And Marketing Ltd Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
KR101585221B1 (ko) 2014-02-27 2016-01-13 권희완 지압대 겸용 지압 베개
EP3560555A1 (de) * 2018-04-26 2019-10-30 LifeArc Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
ATE86484T1 (de) 1987-08-08 1993-03-15 Akzo Nv Kontrazeptives implantat.
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
AU647138B2 (en) 1990-03-16 1994-03-17 Laboratoires Serono Sa Treatment of polycystic ovarian disease
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Also Published As

Publication number Publication date
CZ291709B6 (cs) 2003-05-14
BG100766A (en) 1997-06-30
KR970700507A (ko) 1997-02-12
RU2110274C1 (ru) 1998-05-10
MD1432C2 (ro) 2000-09-30
CZ210396A3 (en) 1997-05-14
HU9601969D0 (en) 1996-09-30
PL178273B1 (pl) 2000-03-31
JPH09508418A (ja) 1997-08-26
RO117420B1 (ro) 2002-03-29
EP0785792A1 (de) 1997-07-30
AP724A (en) 1999-01-18
CA2182183A1 (en) 1995-08-10
CA2182183C (en) 2003-09-16
GR3030164T3 (en) 1999-08-31
ATE179610T1 (de) 1999-05-15
DE69509544D1 (de) 1999-06-10
CN1144486A (zh) 1997-03-05
MD1432B2 (en) 2000-03-31
AP9600840A0 (en) 1996-07-31
EP0785792A4 (de) 1997-07-30
HUT74622A (en) 1997-01-28
NZ281441A (en) 1999-09-29
US5681817A (en) 1997-10-28
LT4182B (en) 1997-06-25
PL315792A1 (en) 1996-12-09
TJ242B (en) 1999-11-24
ES2132645T3 (es) 1999-08-16
DE69509544T2 (de) 1999-09-02
WO1995020972A1 (en) 1995-08-10
FI963036A0 (fi) 1996-08-01
BG62238B1 (bg) 1999-06-30
FI963036A (fi) 1996-08-01
SK96296A3 (en) 1997-07-09
LT96133A (en) 1997-01-27
EP0785792B1 (de) 1999-05-06
LV11782A (lv) 1997-06-20
AU1838695A (en) 1995-08-21
AU689229B2 (en) 1998-03-26
DK0785792T3 (da) 1999-10-18
LV11782B (en) 1997-12-20
JP3130048B2 (ja) 2001-01-31
BR9506606A (pt) 1997-09-09

Similar Documents

Publication Publication Date Title
US5681817A (en) Treatment of ovarian estrogen dependent conditions
US5468736A (en) Hormone replacement therapy
US8450299B2 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Broekmans GnRH agonists and uterine leiomyomas
Maheux et al. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study
Friedman Treatment of uterine myomas with GnRH agonists
Lee Contraceptive and endometrial effects of medroxyprogesterone acetate
RU2181598C2 (ru) Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения
Judd Gonadotropin-releasing hormone agonists: Strategies formanaging the hypoestrogenic effects of therapy
Balmaceda et al. The effects of chronic administration of LH-RH agonists and antagonists on the menstrual cycle and endometrium of the rhesus monkey
Shaw Danazol in dysfunctional uterine bleeding
AU2011203526A1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens